SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Privia Health Group, Inc. (PRVA) trades at a trailing P/E of 121.7, forward P/E of 66.0. Trailing earnings yield is 0.82%, forward earnings yield 1.52%. PEG 1.91. Graham Number is $5.18.
Criteria proven by this page:
- VALUE (31/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 121.7); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.82%).
- Forward P/E 66.0 (down from trailing 121.7) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.91 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 0.82% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 1.52% as earnings recover.
- Analyst consensus target $31.00 (+34.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 66/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
31/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PRVA
Valuation Multiples
P/E (TTM)121.7
Forward P/E66.0
PEG Ratio1.91
Forward PEG0.70
P/B Ratio3.78
P/S Ratio1.32
EV/EBITDA47.7
Per Share Data
EPS (TTM)$0.19
Forward EPS (Est.)$0.35
Book Value / Share$6.42
Revenue / Share$17.23
FCF / Share$1.32
Yields & Fair Value
Earnings Yield0.82%
Forward Earnings Yield1.52%
Dividend Yield0.00%
Graham Number$5.18
SharesGrow IV$22.51 (-2.6%)
Analyst Target$31.00 (+34.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-776.6 |
0.00 |
26.71 |
3.59 |
- |
| 2019 |
294.9 |
-0.81 |
22.06 |
3.09 |
- |
| 2020 |
77.8 |
0.27 |
16.57 |
2.98 |
- |
| 2021 |
-14.8 |
0.02 |
6.54 |
2.89 |
- |
| 2022 |
-292.8 |
3.12 |
5.04 |
1.85 |
- |
| 2023 |
116.5 |
-0.41 |
4.79 |
1.62 |
- |
| 2024 |
162.3 |
-4.06 |
3.68 |
1.34 |
- |
| 2025 |
126.4 |
2.17 |
3.93 |
1.36 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.03 |
$657.61M |
$-3.04M |
-0.5% |
| 2019 |
$0.08 |
$786.36M |
$8.24M |
1% |
| 2020 |
$0.30 |
$817.08M |
$31.24M |
3.8% |
| 2021 |
$-1.77 |
$966.22M |
$-190.65M |
-19.7% |
| 2022 |
$-0.11 |
$1.36B |
$-12.06M |
-0.9% |
| 2023 |
$0.19 |
$1.66B |
$23.08M |
1.4% |
| 2024 |
$0.11 |
$1.74B |
$14.39M |
0.8% |
| 2025 |
$0.18 |
$2.12B |
$22.92M |
1.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.35 |
$0.30 – $0.45 |
$2.38B |
$2.36B – $2.39B |
10 |
| 2027 |
$0.45 |
$0.36 – $0.60 |
$2.63B |
$2.56B – $2.75B |
9 |
| 2028 |
$0.65 |
$0.51 – $0.87 |
$2.94B |
$2.94B – $2.94B |
5 |
| 2029 |
$0.79 |
$0.76 – $0.83 |
$3.13B |
$3.03B – $3.24B |
1 |
| 2030 |
$0.95 |
$0.91 – $0.99 |
$3.45B |
$3.33B – $3.57B |
1 |
